Translational research in complex etiopathogenesis and therapy of hematological malignancies: The specific role of tyrosine kinases signaling and inhibition

Medical Oncology

Volumn 26, Issue 4, 2009, Pages 437-444

  Stankov, Karmen ^a,b   Stankov, Sunčica ^c   Popović, Stevan ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^c University Novi Sad   (Serbia)

Author keywords

Leukemia; Protein kinase inhibitors; Receptor protein tyrosine kinases

Indexed keywords

DASATINIB; FINGOLIMOD; IMATINIB; LESTAURTINIB; MIDOSTAURIN; NILOTINIB; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; KARYOTYPE; LEUKEMIA CELL; MAST CELL LEUKEMIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RNA TRANSLATION;

HEMATOLOGIC NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH;

EID: 70949105699     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9143-2     Document Type: Review

References (57)

1. Y Landry JP Gies 2008 Drugs and their molecular targets: an updated overview Fundam Clin Pharmacol 22 1 18 10.1111/j.1472-8206.2007.00548.x 10.1111/j.1472-8206.2007.00548.x 1:CAS:528:DC%2BD1cXis12ktr0%3D 18251718 (Pubitemid 351171284)
2. T Hughes, et al. 2006 Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 28 37 10.1182/blood-2006-01-0092 10.1182/blood-2006-01-0092 1:CAS:528:DC%2BD28XmsVOmt7Y%3D 16522812 (Pubitemid 43990609)
3. K Strebhardt A Ullrich 2008 Paul Ehrlich's magic bullet concept: 100 years of progress Nature Rev Cancer 8 473 80 10.1038/nrc2394 10.1038/nrc2394 1:CAS:528:DC%2BD1cXmt1Oksbw%3D (Pubitemid 351752547)
4. RK Thomas, et al. 2007 High-throughput oncogene mutation profiling in human cancer Nat Genet 39 347 51 10.1038/ng1975 10.1038/ng1975 1:CAS:528:DC%2BD2sXitVOktrs%3D 17293865 (Pubitemid 46328493)
5. A Quintas-Cardama H Kantarjian J Cortes 2007 Flying under the radar: the new waveof BCR-ABL inhibitors Nat Rev Drug Discov 6 834 48 10.1038/nrd2324 10.1038/nrd2324 1:CAS:528:DC%2BD2sXhtFSgsLzJ 17853901 (Pubitemid 47500507)
6. R Hehlmann A Hochhaus M Baccarani 2007 Chronic myeloid leukaemia Lancet 370 342 50 10.1016/S0140-6736(07)61165-9 10.1016/S0140-6736(07)61165-9 1:CAS:528:DC%2BD2sXot1yltro%3D 17662883 (Pubitemid 47094995)
7. G Wernig, et al. 2008 Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera Cancer Cell 13 311 20 10.1016/j.ccr.2008.02.009 10.1016/j.ccr.2008.02.009 1:CAS:528:DC%2BD1cXkslSjtrs%3D 18394554
8. I Geron, et al. 2008 Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors Cancer Cell 13 321 30 10.1016/j.ccr.2008.02.017 10.1016/j.ccr.2008.02.017 1:CAS:528: DC%2BD1cXkslSjtrg%3D 18394555
9. P Neviani, et al. 2007 FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia J Clin Invest 117 2408 21 10.1172/JCI31095 10.1172/JCI31095 1:CAS:528:DC%2BD2sXhtVCms7vM 17717597 (Pubitemid 47494343)
10. A Arora EM Scholar 2005 Role of tyrosine kinase inhibitors in cancer therapy J Pharmacol Exp Ther 315 971 9 10.1124/jpet.105.084145 10.1124/jpet.105.084145 1:CAS:528:DC%2BD2MXhtlalur3L 16002463 (Pubitemid 41635382)
11. JF Apperley 2007 Mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet 8 1018 29 10.1016/S1470-2045(07)70342-X 10.1016/S1470-2045(07) 70342-X 1:CAS:528:DC%2BD2sXht1GrsbjL (Pubitemid 47629897)
12. T Force DS Krause RA Van Etten 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition Nat Rev Cancer 7 332 44 10.1038/nrc2106 10.1038/nrc2106 1:CAS:528:DC%2BD2sXksFSiu7w%3D 17457301 (Pubitemid 46652481)
13. M Valko CJ Rhodes J Moncol M Izakovic M Mazur 2006 Free radicals, metals and antioxidants in oxidative stress-induced cancer Chem Biol Interact 160 1 40 10.1016/j.cbi.2005.12.009 10.1016/j.cbi.2005.12.009 1:CAS:528: DC%2BD28XhsF2hsrY%3D 16430879 (Pubitemid 43227479)
14. D Fabbro D Parkinson A Matter 2002 Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol 2 374 81 10.1016/S1471-4892(02) 00179-0 10.1016/S1471-4892(02)00179-0 1:CAS:528:DC%2BD38XlsVGqtL8%3D 12127869 (Pubitemid 34830967)
15. A Levitzki E Mishani 2006 Tyrphostins and other tyrosine kinase inhibitors Annu Rev Biochem 75 93 109 10.1146/annurev.biochem.75.103004.142657 10.1146/annurev.biochem.75.103004.142657 1:CAS:528:DC%2BD28XosVKhsro%3D 16756486 (Pubitemid 44118027)
16. J Meyer, et al. 2007 Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, DTrkA Leukemia 21 2171 80 10.1038/sj.leu.2404882 10.1038/sj.leu.2404882 1:CAS:528:DC%2BD2sXhtVGmsLfF 17673903 (Pubitemid 47423807)
17. KT Doepfner D Boller A Arcaro 2007 Targeting receptor tyrosine kinase signaling in acute myeloid leukemia Crit Rev Oncol Hematol 63 215 30 10.1016/j.critrevonc.2007.05.005 10.1016/j.critrevonc.2007.05.005 17658267 (Pubitemid 47126864)
18. AM Martelli PL Tazzari C Evangelisti F Chiarini WL Blalock AM Billi L Manzoli JA McCubrey L Cocco 2007 Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside Curr Med Chem 14 2009 23 10.2174/ 092986707781368423 10.2174/092986707781368423 1:CAS:528:DC%2BD2sXosFequ7w%3D 17691943 (Pubitemid 47578159)
19. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. Leukemia. 2008; doi: 10.1038/leu.2008.243.
20. I Matsumura M Mizuki Y Kanakura 2008 Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies Cancer Sci 99 479 85 10.1111/j.1349-7006.2007.00717.x 10.1111/j.1349-7006.2007.00717.x 1:CAS:528:DC%2BD1cXjt1ehsrg%3D 18177485 (Pubitemid 351228563)
21. ZQ Ning J Li RJ Arceci 2001 Signal transducer and activator of transcription 3 activation is required for Asp (816) mutant c-kit-mediated cytokine-independent survival and proliferation in human leukemia cells Blood 97 3559 67 10.1182/blood.V97.11.3559 10.1182/blood.V97.11.3559 1:CAS:528:DC%2BD3MXktFOkurw%3D 11369651
22. M Blagosklony 2004 Prospective strategies to enforce selectively cell death in cancer cells Oncogene 23 2967 75 10.1038/sj.onc.1207520 10.1038/sj.onc.1207520 (Pubitemid 38638856)
23. E Weisberg PW Manley SW Cowan-Jacob A Hochhaus JD Griffin 2007 Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia Nat Rev Cancer 7 345 56 10.1038/nrc2126 10.1038/nrc2126 1:CAS:528:DC%2BD2sXksFSiu7o%3D 17457302 (Pubitemid 46652483)
24. LQM Chow SG Eckhardt 2007 Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 884 96 10.1200/JCO.2006.06.3602 10.1200/JCO.2006.06. 3602 1:CAS:528:DC%2BD2sXjvVKmtLY%3D 17327610 (Pubitemid 350002890)
25. AM O'Farrell, et al. 2003 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 101 3597 605 10.1182/blood-2002-07-2307 10.1182/blood-2002-07-2307 12531805 (Pubitemid 36857948)
26. MM Schittenhelm, et al. 2006 Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies Cancer Res 66 473 81 10.1158/0008-5472.CAN-05-2050 10.1158/0008-5472.CAN-05-2050 1:CAS:528:DC%2BD28XhsFWltw%3D%3D 16397263 (Pubitemid 43166056)
27. A Quintas-Cardama J Cortes 2008 Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases Future Oncol 4 611 21 10.2217/14796694.4.5.611 10.2217/14796694.4.5.611 1:CAS:528: DC%2BD1cXht1Glu7fI 18922118
28. DL White VA Saunders SR Quinn PW Manley TP Hughes 2007 Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs Blood 109 3609 10 10.1182/blood-2006-11-058032 10.1182/blood-2006-11-058032 1:CAS:528:DC%2BD2sXksFWhsLY%3D 17409347 (Pubitemid 46572560)
29. S Hu, et al. 2008 Comparison of antitumor effects on multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia Cancer Ther 7 1110 20 10.1158/1535-7163.MCT-07-2218 10.1158/1535-7163.MCT-07-2218 1:CAS:528: DC%2BD1cXlvFanu7o%3D
30. S Knapper KI Mills AF Gilkes SJ Austin V Walsh AK Burnett 2006 The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases Blood 108 3494 503 10.1182/blood-2006-04-015487 10.1182/blood-2006-04-015487 1:CAS:528:DC%2BD28Xht1ahsLzL 16868253 (Pubitemid 44776892)
31. D Milojkovic J Apperley 2008 State-of-the-art in the treatment of chronic myeloid leukaemia Curr Opin Oncol 20 112 21 10.1097/CCO.0b013e3282f1fe8a 1:CAS:528:DC%2BD2sXhtlGns73N 18043265 (Pubitemid 350190990)
32. A Hochhaus, et al. 2008 Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 22 1200 6 10.1038/leu.2008.84 10.1038/leu.2008.84 1:CAS:528:DC%2BD1cXntVCjurw%3D 18401416 (Pubitemid 351833788)
33. JF Apperley 2007 Mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet 8 1116 28 10.1016/S1470-2045(07)70379-0 10.1016/S1470-2045(07) 70379-0 1:CAS:528:DC%2BD2sXhsVWjurzP (Pubitemid 350182968)
34. X Cao KQ Tanis AJ Koleske J Colicelli 2008 Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms J Biol Chem 283 31401 7 10.1074/jbc.M804002200 10.1074/jbc.M804002200 1:CAS:528:DC%2BD1cXhtlCjsb%2FN 18796434
35. M Azam, et al. 2006 Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance Proc Natl Acad Sci USA 103 9244 9 10.1073/pnas.0600001103 10.1073/pnas.0600001103 1:CAS:528: DC%2BD28XmsVWjtrc%3D 16754879 (Pubitemid 43902563)
36. N Widmer, et al. 2008 Relationship of imatinib-free plasma levels and target phenotype with efficacy and tolerability Br J Cancer 98 1633 40 10.1038/sj.bjc.6604355 10.1038/sj.bjc.6604355 1:CAS:528:DC%2BD1cXlvVWhsbs%3D 18475296 (Pubitemid 351684684)
37. L Wang, et al. 2008 Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia Clin Pharmacol Ther 83 258 64 10.1038/sj.clpt.6100268 10.1038/sj.clpt.6100268 1:CAS:528:DC%2BD1cXitFKjtb4%3D 17568400
38. RA Larson, et al. 2008 Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 111 4022 8 10.1182/blood-2007-10-116475 10.1182/blood-2007-10-116475 1:CAS:528:DC%2BD1cXkvFeisrg%3D 18256322
39. J Reilly 2003 Receptor tyrosine kinases in normal and malignant haematopoiesis Blood Rev 17 241 8 10.1016/S0268-960X(03)00024-9 10.1016/S0268-960X(03)00024-9 14556779 (Pubitemid 37356395)
40. PH Corell RF Paulson X Wei 2006 Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies Gene 374 26 38 10.1016/j.gene.2006.01.023 10.1016/j.gene.2006.01.023 (Pubitemid 43737116)
41. DG Gilliland 2001 Hematologic malignancies Curr Opin Hematol 8 189 91 10.1097/00062752-200107000-00001 10.1097/00062752-200107000-00001 1:STN:280:DC%2BD3Mrht1elsg%3D%3D 11561153 (Pubitemid 32762958)
42. O Kosmider, et al. 2005 Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice Cancer Cell 8 467 78 10.1016/j.ccr.2005.11.009 10.1016/j.ccr.2005.11.009 1:CAS:528:DC%2BD28Xhslemuw%3D%3D 16338660 (Pubitemid 41773450)
43. A Renneville, et al. 2008 Cooperating gene mutations in acute myeloid leukemia: a review of the literature Leukemia 22 915 31 10.1038/leu.2008.19 10.1038/leu.2008.19 1:CAS:528:DC%2BD1cXlvVSrsLY%3D 18288131 (Pubitemid 351709343)
44. MM Patnaik A Tefferi A Pardanani 2007 Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders Curr Cancer Drug Targets 7 492 503 10.2174/156800907781386614 10.2174/ 156800907781386614 1:CAS:528:DC%2BD2sXhtVKqsLjF 17691909 (Pubitemid 47196209)
45. T Kindler, et al. 2003 Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML Blood 101 2960 2 10.1182/blood-2002-05-1469 10.1182/blood-2002-05-1469 1:CAS:528:DC%2BD3sXjtFCqsbk%3D 12480706 (Pubitemid 36857980)
46. BD Smolich, et al. 2001 The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts Blood 97 1413 21 10.1182/blood.V97.5.1413 10.1182/blood.V97.5.1413 1:CAS:528:DC%2BD3MXhs12ltLc%3D 11222388 (Pubitemid 32183767)
47. L Mollgard, et al. 2008 The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia Cancer Chemother Pharmacol 62 439 48 10.1007/s00280-007-0623-4 10.1007/s00280-007-0623-4 17960382 (Pubitemid 351871802)
48. DA Tuveson, et al. 2001 STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications Oncogene 20 5054 8 10.1038/sj.onc.1204704 10.1038/sj.onc.1204704 1:CAS:528: DC%2BD3MXmtlCks7g%3D 11526490 (Pubitemid 32769795)
49. JF Apperley, et al. 2002 Response to imatinib mesylate in patients with chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor receptor beta N Engl J Med 347 481 7 10.1056/NEJMoa020150 10.1056/NEJMoa020150 1:CAS:528:DC%2BD38XmtV2nt7g%3D 12181402 (Pubitemid 34879335)
50. J De R Zanjani M Hibbard BH Davis 2007 Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia Am J Clin Pathol 128 550 7 10.1309/JVALJNL4ELQMD536 10.1309/JVALJNL4ELQMD536 1:CAS:528: DC%2BD2sXht1emtLbO 17875504 (Pubitemid 47584431)
51. A Fernandez, et al. 2007 Rational drug redesign to overcome drug resistance in cancer therapy: Imatinib moving target Cancer Res 67 4028 33 10.1158/0008-5472.CAN-07-0345 10.1158/0008-5472.CAN-07-0345 1:CAS:528: DC%2BD2sXltVyku70%3D 17483313 (Pubitemid 46815047)
52. M Levis, et al. 2002 A FLT3- targeted tyrosine kinase inhibitor is cytotoxic to leukaemia cells in vitro and in vivo Blood 99 3885 91 10.1182/blood.V99.11.3885 10.1182/blood.V99.11.3885 1:CAS:528: DC%2BD38XktFyrsr0%3D 12010785 (Pubitemid 35332023)
53. M Levis P Brown BD Smith 2006 Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors Blood 108 3477 83 10.1182/blood-2006-04-015743 10.1182/blood-2006-04-015743 1:CAS:528:DC%2BD28Xht1egu77N 16857987 (Pubitemid 44776890)
54. NP Shah CL Sawyers 2003 Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias Oncogene 22 7389 95 10.1038/sj.onc.1206942 10.1038/sj.onc.1206942 1:CAS:528:DC%2BD3sXotlajurk%3D 14576846 (Pubitemid 37487164)
55. P Lin, et al. 2008 Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations Mod Pathol 21 1029 36 10.1038/modpathol.2008. 92 10.1038/modpathol.2008.92 1:CAS:528:DC%2BD1cXovV2msrs%3D 18536654
56. NL Komarova D Wodarz 2005 Drug resistance in cancer: principles of emergence and prevention Proc Natl Acad Sci USA 102 9714 19 10.1073/pnas. 0501870102 10.1073/pnas.0501870102 1:CAS:528:DC%2BD2MXmsVaktbY%3D 15980154 (Pubitemid 40981746)
57. F Levi F Lucchini E Negri T Barbui C La Vecchia 2000 Trends in mortality from leukemia in subsequent age groups Leukemia 14 1980 5 10.1038/sj.leu.2401915 10.1038/sj.leu.2401915 1:STN:280:DC%2BD3crhtFOrsg%3D%3D 11069035